Johanna Friedl-Naderer

Johanna Friedl-Naderer

Former Executive Vice President and Chief Operating OfficeratVir Biotechnology· In proxies 2022–2023

Pay in FY2023-13% from the year before · Vir Biotechnology stock -60.3% the same year

Johanna Friedl-Naderer was paid $4.4M in FY2023 (Dec), down 13%. Vir Biotechnology stock fell 60.3% that year.

Pay$100 in the stock at the end of FY21 → $24
Pay is from the Summary Compensation Table of each Vir Biotechnology proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Vir BiotechnologyPublic company · 4 yr
    • Former Executive Vice President and Chief Operating Officer2022 – Present · 4 yrStock in role -70%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?